Biodistribution of 89 Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010; 87 :586–592. doi: 10.1038/clpt.2010.12. [ Cross Ref ]Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, et al. ...
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. We performed a feasibility study to determine the optimal dosage and time of administration of the monoclonal antibody zirconium-89 ((89)Zr)-trastuzumab to... EC Dijkers,TH Oude...
To confirm imaging specificity we also evaluated brain uptake of a non-amyloid targeting [89Zr]-labeled antibody (trastuzumab) as a negative control, additionally we performed a competitive blocking study with non-radiolabeled Df-Bz-JRF/AβN/25 and finally we assessed the possible confounding ...
89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer. 2010;46:678–684. Article CAS PubMed Google Scholar Terwisscha van Scheltinga AG, Berghuis P, Nienhuis HH, Timmer-Bosscha H, Pot L, Gaykema SBM, et al. ...
Finally, to demonstrate the practical benefit of more stable complexation for the accurate detection of bone metastases, [89Zr]Zr-DFO*-NCS and [89Zr]Zr-DFO-NCS-labelled trastuzumab and B12 were evaluated in a bone metastasis mouse model where BT-474 breast cancer cells were injected intra...
The development of molecular imaging agents used for imaging of cancer tissue is of great importance for the early detection of cancer. Positron emission tomography (PET) radiopharmaceuticals consists of a positron-emitting radionuclide and a molecularstructure.89Zr-labeled monoclonal antibodies (mAbs), ...
89Zr was complexed with Df-Bz-NCS-trastuzumab at a ratio of 0.22 MBq/μg (6 μCi/μg) of antibody in 0.5 M HEPES buffer pH 7.0 at 37 °C for 1 h with constant agitation on an orbital mixer. Approximately 100 µg of antibody was used per reaction. 89Zr-trastuzumab was purified...
It was demonstrated in a human imaging study with patients suffering from metastatic breast cancer that the ideal time-point for imaging as well as the optimal specific activity of 89Zr-trastuzumab depend on the pretreatment the patient had received. In patients who had already received trastuzumab...